In conjunction with the publication of its full year 2011 results, AstraZeneca has announced new restructuring initiatives which, the company says, are designed to improve productivity and strengthen its commercial, operations and research and development capabilities. The restructuring will result in about 7,300 job losses.
Last updated:
February 3
